Myeloma Paper of the Day, June 17th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Linvoseltamab BCMA TCE (B-cell maturation antigen, T-cell engager) shows ORR 71% (50% ≥CR) in relapsed/refractory myeloma, with impressive median DOR of 29.4 months, while common AEs included CRS (0.9% Grade 3), neutropenia, anemia, infections, and ICANS (7.7%).”
Source: Robert Orlowski/X
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Authors: Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C. Lee, James E. Hoffman, Attaya Suvannasankha, Jeffrey A. Zonder, Mansi R. Shah, Suzanne Lentzsch, Rachid Baz, Joseph J. Maly, Swathi Namburi, Matthew J. Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez-Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D. Yancopoulos, L. Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras and Madhav V. Dhodapkar.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
